Autonomix Medical, Inc. (AMIX)
| Market Cap | 5.45M +7.6% |
| Revenue (ttm) | n/a |
| Net Income | -16.72M |
| EPS | -48.64 |
| Shares Out | 543.30K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 820,945 |
| Open | 11.55 |
| Previous Close | 12.17 |
| Day's Range | 9.21 - 11.79 |
| 52-Week Range | 2.44 - 32.55 |
| Beta | -1.15 |
| Analysts | Buy |
| Price Target | 58.80 (+485.66%) |
| Earnings Date | Aug 14, 2026 |
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company’s technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Med... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AMIX stock is "Buy." The 12-month stock price target is $58.8, which is an increase of 485.66% from the latest price.
News
Autonomix Medical Inc trading resumes
09:41 EDT Autonomix (AMIX) Medical Inc trading resumes
Autonomix Medical Inc trading halted, volatility trading pause
09:31 EDT Autonomix (AMIX) Medical Inc trading halted, volatility trading pause
Why Is Penny Stock Autonomix Medical (AMIX) Up Today?
Autonomix Medical stock took off after the company revealed a new patent in the U.S.
Autonomix issued U.S. patent for nerve sensing, mapping
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands the company’s intellectual ...
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain
Autonomix files to sell 857,462 shares of common stock for holders
17:03 EDT Autonomix (AMIX) files to sell 857,462 shares of common stock for holders
Autonomix Medical Registration statement: Registration filing
Autonomix Medical filed a registration statement on July 28, 2026, providing details about a securities offering with the SEC.
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation
Autonomix secures new U.S. patent for autonomic nervous system technologies
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” further strengthening the company’s intellectual property portfolio supportin...
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications T...
Autonomix granted U.S. patent for overactive bladder diagnosis
Autonomix (AMIX) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bla...
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Aut...
Autonomix enters into $2.6M warrant inducement priced at $6.00
Autonomix (AMIX) Medica announced it has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants that the Company issued on November 19,...
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix granted Canadian patent for neural sensing
Autonomix (AMIX) announced that it has been granted Canadian Patent No. 3,158,197, titled “Endoscopic Sympathectomy Systems and Methods.” The company’s intellectual property portfolio now includes 112...
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
IP portfolio reflects Autonomix's neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic eva...
Autonomix Medical Inc trading halted, news pending
19:50 EDT Autonomix (AMIX) Medical Inc trading halted, news pending
Autonomix develops standalone neural sensing platform
Autonomix (AMIX) announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detec...
Autonomix develops standalone neural sensing platform
Autonomix (AMIX) announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detec...
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path Architecture Supports Future Expansion into Denervation, includ...
Autonomix announces reverse stock split
Autonomix (AMIX) “announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21…
Autonomix Announces Reverse Stock Split
THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
Access the segment here THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing pre...
Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential
Autonomix Medical Annual report: Q4 2026
Autonomix Medical has published its Q4 2026 annual report on May 27, 2026.